COMMUNIQUÉS West-GlobeNewswire
-
Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock
15/10/2025 -
Cytek® Biosciences Expands European Presence with New Facility in Amsterdam to Better Serve Customers and Drive Growth
15/10/2025 -
Teladoc Health to Announce Third Quarter 2025 Financial Results
15/10/2025 -
Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements
15/10/2025 -
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
15/10/2025 -
OrthoPediatrics Corp. to Report Third Quarter Financial Results on October 28, 2025
15/10/2025 -
Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025
15/10/2025 -
Merit Medical Signs Asset Purchase Agreement with PENTAX Medical to Acquire C2 CryoBalloon Technology
15/10/2025 -
PROCEPT BioRobotics® to Report Third Quarter 2025 Financial Results on November 4, 2025
15/10/2025 -
Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest
15/10/2025 -
Vara obtient le marquage CE en tant que seule IA autorisée pour une deuxième lecture indépendante en mammographie et se développe en Europe
15/10/2025 -
Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation
15/10/2025 -
Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation
15/10/2025 -
OSE Immunotherapeutics Reports First Half 2025 Financial Results
15/10/2025 -
OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025
15/10/2025 -
EssilorLuxottica acquires RetinAI, accelerating transformative AI and data-powered eye health solutions
15/10/2025 -
EssilorLuxottica acquiert RetinAI, accélérant dans les solutions transformatrices de santé de l’œil portées par l'IA et la data
15/10/2025 -
HC3 Named Exclusive U.S. Distributor of MICA Advance System for Rapid Legionella Detection
15/10/2025 -
IPSEN - Buy-back programme - Art 5 of MAR - Week 41 - 2025
15/10/2025
Pages